Nebicapone
Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease[1].
Product Specifications
CAS Number
274925-86-9
Product Name Alternative
BIA 3-202
UNSPSC
12352005
Target
COMT
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/nebicapone.html
Purity
99.89
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(C1=CC([N+]([O-])=O)=C(O)C(O)=C1)CC2=CC=CC=C2
Molecular Formula
C14H11NO5
Molecular Weight
273.24
References & Citations
[1]Loureiro AI, et al. Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos. 2006 Nov;34 (11) :1856-62.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY434282 100 µg
SLC6A13 (NM_001190997) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC470841-100 1x 100 µL
Pgp9.5 (UCHL-1) (UCHL1/841), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
